Compass Pathways Launches Proposed $150.0 Million Public Offering

Core Viewpoint - Compass Pathways plc, a biotechnology company, has announced a proposed public offering of $150.0 million of American Depositary Shares (ADSs) to enhance patient access to evidence-based innovation [1] Group 1 - The public offering consists of ADSs, each representing one ordinary share, and pre-funded warrants to purchase ADSs for certain institutional investors [1] - All securities in the offering are being provided by Compass Pathways [1] - The company aims to accelerate patient access to innovative treatments through this funding initiative [1]